TTM
-132.9%
YoY change
−25.23pp
Trough year (2019)
-792.4%
Peak year (2021)
76.3%
Latest annual
-131.3%
EBITDA Margin history chart for Moderna (MRNA) from 2016 to 2025
Latest: -131.3%
EBITDA Margin change chart for Moderna (MRNA) from 2016 to 2025
Latest: −25.23pp
EBITDA Margin history table for Moderna (MRNA) from 2016 to 2025
| 2025 | -131.3% | -25.23pp | ||
| 2024 | -106.1% | -58.15pp | ||
| 2023 | -47.9% | -99.69pp | ||
| 2022 | 51.8% | -24.52pp | ||
| 2021 | 76.3% | +163.82pp | ||
| 2020 | -87.6% | +704.83pp | ||
| 2019 | -792.4% | -487.31pp | ||
| 2018 | -305.1% | -190.74pp | ||
| 2017 | -114.3% | +78.16pp | ||
| 2016 | -192.5% | — |
- 2025-131.3%-25.23pp
- 2024-106.1%-58.15pp
- 2023-47.9%-99.69pp
- 202251.8%-24.52pp
- 202176.3%+163.82pp
- 2020-87.6%+704.83pp
- 2019-792.4%-487.31pp
- 2018-305.1%-190.74pp
- 2017-114.3%+78.16pp
- 2016-192.5%—
EBITDA Margin values are taken from Moderna's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's latest reported EBITDA margin is -132.9%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Moderna (MRNA) EBITDA margin totalled -131.33% – contracted 25.2 percentage points year-over-year.
The record annual EBITDA margin stands at 76.27%, reached in 2021; the historical low of -792.38% was recorded in 2019.
Moderna EBITDA Margin by Year
Moderna EBITDA Margin 2025: -131.3%
In 2025, Moderna reported EBITDA margin of -131.33%, contracted 25.2 percentage points from 2024.
Moderna EBITDA Margin 2024: -106.1%
Moderna EBITDA margin in 2024 was -106.10%, contracted 58.2 percentage points from 2023.
Moderna EBITDA Margin 2023: -47.9%
2023's EBITDA margin for Moderna came in at -47.94%, contracted 99.7 percentage points from 2022.
Moderna EBITDA Margin 2022: 51.8%
Moderna posted EBITDA margin of 51.75% in 2022, contracted 24.5 percentage points from 2021.
Moderna EBITDA Margin 2021: 76.3%
Moderna EBITDA margin in 2021 was 76.27%.
See more financial history for Moderna (MRNA).
Sector peers by EBITDA Margin
Healthcare peers of Moderna (MRNA), ranked by their latest EBITDA margin
| 55.4% | |
| 46.6% | |
| 45.9% | |
| 34.6% | |
| 33.9% | |
| 30.3% | |
| 26.9% | |
| 5.1% |
- 55.4%
- 46.6%
- 45.9%
- 34.6%
- 33.9%
- 26.9%
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation